Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

nucleotides. Nucleic Acids Res 1996; 24:
737±745.
81 Hartmann, G., Krug, A.,Waller-
Fontaine, K. and Endres, S. Oligodeoxynucleotides
enhance lipopolysaccharide-stimulated
synthesis of tumor
necrosis factor: dependence on phosphorothioate
modification and reversal
by heparin. Mol Med 1996; 2: 429±438.
82 Monteith, D. K., Henry, S. P., Howard,
R. B., et al. Immune stimulation
± a class effect of phosphorothioate oligodeoxynucleotides
in rodents. Anticancer
Drug Des 1997; 12: 421±432.
83 Henry, S., Stecker, K., Brooks, D.,
et al. Chemically modified oligonucleotides
exhibit decreased immune stimulation
in mice. J Pharmacol Exp Ther
2000; 292: 468±479.
84 Tam, R. C.,Wu-Pong, S., Pai, B., et al.
Increased potency of an aptameric Grich
oligonucleotide is associated with
novel functional properties of phosphorothioate
linkages. Antisense Nucleic
Acid Drug Dev 1999; 9: 289±300.
85 Zhao, Q.,Temsamani, J., Iadarola, P. L.,
Jiang, Z. and Agrawal, S. Effect of different
chemically modified oligodeoxynucleotides
on immune stimulation.
Biochem Pharmacol 1996; 51: 173±182.
86 Krieg, A. M., Matson, S. and
Fisher, E. Oligodeoxynucleotide modifications
determine the magnitude of
B cell stimulation by CpG motifs. Antisense
Nucleic Acid Drug Dev 1996; 6:
133±139.
87 Yi, A. K., Chang, M., Peckham, D. W.,
Krieg, A. M. and Ashman, R. F. CpG
oligodeoxyribonucleotides rescue mature
spleen B cells from spontaneous
apoptosis and promote cell cycle entry
[published erratum appears in J Immunol
1999; 163(2): 1093]. J Immunol
1998; 160: 5898±5906.
88 Hartmann, G.,Weeratna, R. D., Ballas,
Z. K., et al. Delineation of a CpG
phosphorothioate oligodeoxynucleotide
for activating primate immune responses
in vitro and in vivo. J Immunol
2000; 164: 1617±1624.
89 Goeckeritz, B. E., Flora, M., Witherspoon,
K., et al. Multivalent cross-linking
of membrane Ig sensitizes murine
B cells to a broader spectrum of CpG-
References
containing oligodeoxynucleotide motifs,
including their methylated counterparts,
for stimulation of proliferation
and Ig secretion. Int Immunol 1999; 11:
1693±1700.
90 Ballas, Z. K., Rasmussen,W. L. and
Krieg, A. M. Induction of NK activity
in murine and human cells by CpG
motifs in oligodeoxynucleotides and
bacterial DNA. J Immunol 1996; 157:
1840±1845.
91 Sester, D. P., Beasley, S. J., Sweet, M. J.,
et al. Bacterial/CpG DNA down-modulates
colony stimulating factor-1 receptor
surface expression on murine bone
marrow-derived macrophages with concomitant
growth arrest and factor-independent
survival. J Immunol 1999; 163:
6541±6550.
92 Boggs, R. T., McGraw, K., Condon, T.,
et al. Characterization and modulation
of immune stimulation by modified oligonucleotides.
Antisense Nucleic Acid
Drug Dev 1997; 7: 461±471.
93 Yamamoto, S.,Yamamoto,T., Kataoka,T.,
et al. Unique palindromic sequences in
synthetic oligonucleotides are required
to induce INF and augment INFmediated
natural killer activity. J Immunol
1992; 148: 4072±4076.
94 Sun, S., Zhang, X., Tough, D. F. and
Sprent, J. Type I interferon-mediated
stimulation of T cells by CpG DNA.
J Exp Med 1998; 188: 2335±2342.
95 Lipford, G. B., Bauer, M., Blank, C.,
et al. CpG-containing synthetic oligonucleotides
promote B and cytotoxic T cell
responses to protein antigen: a new
class of vaccine adjuvants. Eur J Immunol
1997; 27: 2340±2344.
96 Lipford, G. B., Bendigs, S., Heeg, K.
and Wagner, H. Poly-guanosine motifs
costimulate antigen-reactive CD8 T
cells while bacterial CpG-DNA affect
T-cell activation via antigen-presenting
cell-derived cytokines. Immunology
2000; 101: 46±52.
97 Verthelyi, D., Ishii, K. J., Gursel, M.,
Takeshita, F. and Klinman, D. M.
Human peripheral blood cells differentially
recognize and respond to two distinct
CpG motifs. J Immunol 2001; 166:
2372±2377.
283